The SoFi Technologies and IAC executives will stand election at the media giant's 2025 annual shareholder meeting ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... for the treatment of CF,” said Claire L. Keating, M.D., Co-Director of the Gunnar Esiason Adult Cystic Fibrosis and Lung Program at Columbia ...

However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

If that trend continues, it's unlikely the consumer staples, energy, real estate, healthcare, or materials sectors will beat ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

When the plan is enacted, the term of the current members of Vertex’s board of directors will expire, and a new board will be appointed. However, it is possible current directors could be ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks that will make you rich in 2025. Jurrien Timmer, Director of ...